Cargando…

Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear

BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperl, Matthias F J, Panitz, Christian, Skoluda, Nadine, Nater, Urs M, Pizzagalli, Diego A, Hermann, Christiane, Mueller, Erik M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515133/
https://www.ncbi.nlm.nih.gov/pubmed/35748393
http://dx.doi.org/10.1093/ijnp/pyac038
_version_ 1784798424481136640
author Sperl, Matthias F J
Panitz, Christian
Skoluda, Nadine
Nater, Urs M
Pizzagalli, Diego A
Hermann, Christiane
Mueller, Erik M
author_facet Sperl, Matthias F J
Panitz, Christian
Skoluda, Nadine
Nater, Urs M
Pizzagalli, Diego A
Hermann, Christiane
Mueller, Erik M
author_sort Sperl, Matthias F J
collection PubMed
description BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine, in acquiring emotional memories. Here, we investigated in a between-participants design with 3 groups whether the noradrenergic alpha-2 adrenoreceptor antagonist yohimbine and the dopaminergic D2-receptor antagonist sulpiride modulate long-term fear conditioning and extinction in humans. METHODS: Fifty-five healthy male students were recruited. The final sample consisted of n = 51 participants who were explicitly aware of the contingencies between conditioned stimuli (CS) and unconditioned stimuli after fear acquisition. The participants were then randomly assigned to 1 of the 3 groups and received either yohimbine (10 mg, n = 17), sulpiride (200 mg, n = 16), or placebo (n = 18) between fear acquisition and extinction. Recall of conditioned (non-extinguished CS+ vs CS−) and extinguished fear (extinguished CS+ vs CS−) was assessed 1 day later, and a 64-channel electroencephalogram was recorded. RESULTS: The yohimbine group showed increased salivary alpha-amylase activity, confirming a successful manipulation of central noradrenergic release. Elevated fear-conditioned bradycardia and larger differential amplitudes of the N170 and late positive potential components in the event-related brain potential indicated that yohimbine treatment (compared with a placebo and sulpiride) enhanced fear recall during day 2. CONCLUSIONS: These results suggest that yohimbine potentiates cardiac and central electrophysiological signatures of fear memory consolidation. They thereby elucidate the key role of noradrenaline in strengthening the consolidation of conditioned fear associations, which may be a key mechanism in the etiology of fear-related disorders.
format Online
Article
Text
id pubmed-9515133
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95151332022-09-28 Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear Sperl, Matthias F J Panitz, Christian Skoluda, Nadine Nater, Urs M Pizzagalli, Diego A Hermann, Christiane Mueller, Erik M Int J Neuropsychopharmacol Regular Research Articles BACKGROUND: Hyperconsolidation of aversive associations and poor extinction learning have been hypothesized to be crucial in the acquisition of pathological fear. Previous animal and human research points to the potential role of the catecholaminergic system, particularly noradrenaline and dopamine, in acquiring emotional memories. Here, we investigated in a between-participants design with 3 groups whether the noradrenergic alpha-2 adrenoreceptor antagonist yohimbine and the dopaminergic D2-receptor antagonist sulpiride modulate long-term fear conditioning and extinction in humans. METHODS: Fifty-five healthy male students were recruited. The final sample consisted of n = 51 participants who were explicitly aware of the contingencies between conditioned stimuli (CS) and unconditioned stimuli after fear acquisition. The participants were then randomly assigned to 1 of the 3 groups and received either yohimbine (10 mg, n = 17), sulpiride (200 mg, n = 16), or placebo (n = 18) between fear acquisition and extinction. Recall of conditioned (non-extinguished CS+ vs CS−) and extinguished fear (extinguished CS+ vs CS−) was assessed 1 day later, and a 64-channel electroencephalogram was recorded. RESULTS: The yohimbine group showed increased salivary alpha-amylase activity, confirming a successful manipulation of central noradrenergic release. Elevated fear-conditioned bradycardia and larger differential amplitudes of the N170 and late positive potential components in the event-related brain potential indicated that yohimbine treatment (compared with a placebo and sulpiride) enhanced fear recall during day 2. CONCLUSIONS: These results suggest that yohimbine potentiates cardiac and central electrophysiological signatures of fear memory consolidation. They thereby elucidate the key role of noradrenaline in strengthening the consolidation of conditioned fear associations, which may be a key mechanism in the etiology of fear-related disorders. Oxford University Press 2022-06-24 /pmc/articles/PMC9515133/ /pubmed/35748393 http://dx.doi.org/10.1093/ijnp/pyac038 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Research Articles
Sperl, Matthias F J
Panitz, Christian
Skoluda, Nadine
Nater, Urs M
Pizzagalli, Diego A
Hermann, Christiane
Mueller, Erik M
Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title_full Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title_fullStr Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title_full_unstemmed Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title_short Alpha-2 Adrenoreceptor Antagonist Yohimbine Potentiates Consolidation of Conditioned Fear
title_sort alpha-2 adrenoreceptor antagonist yohimbine potentiates consolidation of conditioned fear
topic Regular Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515133/
https://www.ncbi.nlm.nih.gov/pubmed/35748393
http://dx.doi.org/10.1093/ijnp/pyac038
work_keys_str_mv AT sperlmatthiasfj alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT panitzchristian alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT skoludanadine alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT naterursm alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT pizzagallidiegoa alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT hermannchristiane alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear
AT muellererikm alpha2adrenoreceptorantagonistyohimbinepotentiatesconsolidationofconditionedfear